A Retrospective Evaluation of Chemotherapy Regimens in Unselected Patients with Metastatic Non-Small Cell Lung Cancer
A Retrospective Evaluation of Chemotherapy Regimens in Unselected Patients with Metastatic Non-Small Cell Lung Cancer作者机构：Clinical Oncology and Nuclear Medicine Department University of Alexandria Faculty of Medicine Alexandria Egypt Preventive Medicine Division University of Alabama at Birmingham Birmingham AL USA Hematology oncology Division Wake Forest University Comprehensive Cancer Center Winston Salem NC USA
出 版 物：《Journal of Cancer Therapy》 (癌症治疗（英文）)
年 卷 期：2018年第9卷第3期
页 面：314-322页
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
主 题：NSCLC-Lung Cancer Chemotherapy-Comorbidities
摘 要：Background: Randomized clinical trials have demonstrated the benefits of chemotherapy in carefully selected non-small cell lung cancer (NSCLC) patients. How generalizable these results are to other NSCLC patients is unresolved. Methods: The outcomes of patients treated with standard chemotherapy regimens (paclitaxel / carboplatin;gemcitabine / carboplatin;pemetrexed / carboplatin;paclitaxel / carboplatin / bevacizumab) off study as first line therapy between 2002 and 2012 at our institution were compared to the reported results of trials supporting the FDA approval of these drugs and/or regimens. Results: In our population, 38.1% of the patients had hypertension, 11.9% of the patients were diabetic, 23.7% had chronic obstructive pulmonary disease (COPD), 11.9% had coronary artery disease (CAD) and 2.1% had renal or liver disease. Notably, the presence of a single or multiple comorbidities was associated with low overall survival compared to matched patients with no comorbidities (p = 0.007). Conclusion: The presence of single or multiple comorbidities is associated with inferior overall survival compared to matched groups without such pre-existing conditions.
维普期刊数据库